Indegene Ltd
Indegene Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Growth outlook is positive with robust deal win pipeline and steady to increasing performance quarter-on-quarter. EBITDA margins expected to begin sequential improvement from Q1 FY27, with stable-to-increasing earnings thereafter.
From Indegene Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Growth outlook is positive with robust deal win pipeline and steady to increasing performance quarter-on-quarter.
- Strong customer conversations and joint propositions post BioPharm acquisition signal promising momentum.
- Pipeline in large accounts is robust with some previously impacted customers gaining momentum.
- Volume increases expected from renewals converting shorter-term engagements into annual annuity business.
- No risk of drag on growth from brand/business acquisitions like Cult and BioPharm; these bring new capabilities and enterprise engagement conversations.
- Mid- to higher-teens growth is the historical guidance; recent 18%+ growth signals potential for stronger market ahead but no explicit future guidance given.
2 more points from Indegene Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Indegene Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Indegene is making significant strategic investments primarily in senior talent across go-to-market teams, solutioning, and domain experts in both Enterprise Commercial Solutions and Enterprise Medical Solutions.
- They have invested in capabilities building, including hiring specialized senior resources for operations and go-to-market functions.
- Investments are directed towards new technologies integration, notably in Gen AI licensing, cloud infrastructure, and enhanced security costs to support growth and infrastructure scalability.
- The total impact of these investments resulted in a 1.5% EBITDA margin compression, which has already been accounted for and is not expected to increase.
2 more points from Indegene Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Indegene Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Renewals have been fairly stable and in line with expectations for the order book at the start of the year (Q3 FY26).
- New customers converting short-term engagements (3-6 months) into annual annuity business contribute to volume increases.
- Order book value is steady, supported by a robust pipeline in large accounts, with momentum returning in previously challenged customers.
- There is no specific drag anticipated on growth from renewals or brand and enterprise businesses.
- Gen AI initiatives and centralization trends provide opportunities for volume expansion upstream and downstream across enterprise commercial solutions.
2 more points from Indegene Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Indegene Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.0K Cr, net profit ₹80 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Indegene Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Vijaya Diagnostic Centre Ltd (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnost.'s Q3 FY26 earnings call — and…
- Chandan Healthcare Ltd (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
- Rainbow Childrens Medicare Ltd (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Krsnaa Diagnostics Ltd (Q3 FY26)
Retail segment showing strong momentum, with retail revenue growing nearly 8x YoY in Q3 FY '26, contributing 8% of total revenue; network expanded to over…
Arthneeti Pro · Annual
Indegene Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Indegene Ltd Q3 FY26 results?
Growth outlook is positive with robust deal win pipeline and steady to increasing performance quarter-on-quarter. EBITDA margins expected to begin sequential improvement from Q1 FY27, with stable-to-increasing earnings thereafter.
What is Indegene Ltd share price analysis?
Indegene Ltd currently shows a neutral. The stock trades at a P/E of 31.3 with a market cap of ₹13,016 Cr. Investors should review the full earnings analysis for detailed insights.
Is Indegene Ltd planning capital expenditure?
Indegene is making significant strategic investments primarily in senior talent across go-to-market teams, solutioning, and domain experts in both Enterprise Commercial Solutions and Enterprise Medical Solutions.
Keep Indegene Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.